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Abstract 
Background: Carbapenem-resistant Enterobacteriaceae (CRE) is prevalent around the world. Rapid and accurate 
detection of CRE is urgently needed to provide effective treatment. Automated identification systems have been 
widely used in clinical microbiology laboratories for rapid and high-efficient identification of pathogenic bacte-
ria. However, critical evaluation and comparison are needed to determine the specificity and accuracy of different 
systems. The aim of this study was to evaluate the performance of three commonly used automated identification 
systems on the detection of CRE.
Methods: A total of 81 non-repetitive clinical CRE isolates were collected from August 2011 to August 2012 in a 
Chinese university hospital, and all the isolates were confirmed to be resistant to carbapenems by the agar dilution 
method. The potential presence of carbapenemase genotypes of the 81 isolates was detected by PCR and sequenc-
ing. Using 81 clinical CRE isolates, we evaluated and compared the performance of three automated identification 
systems, MicroScan WalkAway 96 Plus, Phoenix 100, and Vitek 2 Compact, which are commonly used in China. To 
identify CRE, the comparator methodology was agar dilution method, while the PCR and sequencing was the com-
parator one to identify CPE.
Results: PCR and sequencing analysis showed that 48 of the 81 CRE isolates carried carbapenemase genes, including 
23 (28.4 %) IMP-4, 14 (17.3 %) IMP-8, 5 (6.2 %) NDM-1, and 8 (9.9 %) KPC-2. Notably, one Klebsiella pneumoniae isolate 
produced both IMP-4 and NDM-1. One Klebsiella oxytoca isolate produced both KPC-2 and IMP-8. Of the 81 clinical 
CRE isolates, 56 (69.1 %), 33 (40.7 %) and 77 (95.1 %) were identified as CRE by MicroScan WalkAway 96 Plus, Phoenix 
100, and Vitek 2 Compact, respectively. The sensitivities/specificities of MicroScan WalkAway, Phoenix 100 and Vitek 2 
were 93.8/42.4 %, 54.2/66.7 %, and 75.0/36.4 %, respectively.
Conclusions: The MicroScan WalkAway and Viteck2 systems are more reliable in clinical identification of CRE, 
whereas additional tests are required for the Pheonix 100 system. Our study provides a useful guideline for using auto-
mated identification systems for CRE identification.
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Background
Carbapenems are the most efficient antibiotics in treat-
ment of serious infections caused by multidrug-resist-
ant Gram-negative bacteria [1]. In recent years, the 
emergence and dissemination of carbapenem-resistant 
Enterobacteriaceae (CRE) have increased remarkably 
[2–5]. CRE are a subgroup of Enterobacteriaceae that 
are difficult to treat because of their high level resistance 
to antibiotics. Klebsiella species and Escherichia coli are 
common examples of Enterobacteriaceae, a part of the 
normal human gut bacteria that can become carbape-
nem-resistant. Resistance to carbapenems may be due 
to different mechanisms, and one of the mechanisms is 
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through the production of carbapenemase which was 
called carbapenemase-producing Enterobacteriaceae 
(CPE) [6]. Carbapenemases are heterogeneous enzymes 
capable of hydrolysing cabapenems, such as imipenem 
and meropenem [6]. Klebsiella pneumoniae carbapen-
emase (KPC) were first described in K. pneumoniae, 
which were predominantly involved in K. pneumoniae 
and detected in other genera of the Enterobacteriaceae 
now [7–9]. In addition to KPC, other enzymes, such as 
NDM-1, VIM, and IMP, can also hydrolyze carbapen-
ems and lead to the development of CRE [3, 8]. Further, 
CRE often has the characteristics of multi-drug resistant 
(MDR) and/or extensively drug-resistant (XDR), making 
it more difficult for effective treatment [9].
Therefore, rapid and accurate detection of carbapenem 
non-susceptible Enterobacteriaceae will play an impor-
tant role in the infection control and prevention of mul-
tidrug resistance dissemination. The automated systems 
are widely used in many clinical laboratories for identifi-
cation of bacterial species and antimicrobial susceptibil-
ity testing (AST). Phoenix 100, Vitek-2, and MicroScan 
WalkAway 96 Plus are the most common automated 
identification systems currently used in China [10–15]. 
However, critical evaluation of these systems is lacking to 
determine their sensitivity and specificity. Thus, the aim 
of the present study is to evaluate the abilities of the three 
systems to detect CRE.
Methods
Bacterial strains
A total of 81 non-repetitive clinical isolates of CRE were 
collected and confirmed from August 2011 to August 
2012 at Fujian Medical University Union Hospital in 
Fuzhou, Fujian province, China. All the isolates had been 
preciously confirmed to be resistant to carbapenems 
(Imipenem, Meropenem and Doripenem) by the agar 
dilution method. These isolates included 18 E. coli, 36 K. 
pneumoniae, 21 Enterobacter cloacae, 1 Enterobacter are-
ogenes, 4 K. oxytoca, and 1 Serratia marcescens.
Detection of CRE and CPE by three automated systems
All the CRE isolates were tested duplicatelyin paral-
lel on three automated identification systems. The three 
systems were: MicroScan WalkAway 96 Plus (SIE-
MENS AG FWB, Germany) with NC 50 cards for test-
ing imipenem, meropenem and ertapenem; Phoenix 100 
(Becton, Dickinson and Company, USA) with NMIC/
ID-4 panels for testing imipenem and meropenem; and 
Vitek-2 Compact (Bio Mérieux, France) with AST-GN 
and AST-GN16 cards for testing imipenem and ertap-
enem simultaneously;. All the assays were accomplished 
in the Department of Clinical Laboratory, Fujian Medi-
cal University Union Hospital, Fuzhou, China. The 
carbapenemase-producing Enterobacteriaceae (CPE) 
were predicted by the advanced expert system (AES) of 
the automated systems. The susceptibility breakpoints of 
the three commercial systems were interpreted as rec-
ommended by the Clinical and Laboratory Standards 
Institute (CLSI) [16]. To identify CRE, the comparator 
methodology was agar dilution method, while the PCR 
and sequencing was the comparator one to identify CPE.
DNA extraction
Genomic DNA of the CRE isolates was prepared by sus-
pension of several colonies in 50  µl distilled water. The 
bacterial suspension was heated at 100 °C for 10 min to 
release the genomic DNA as described previously [17].
PCR amplification and sequencing
The presence of carbapenemase genes was detected 
by PCR and sequencing. Gene analysis includes those 
encoding the class A carbapenemases (KPC, GES, SME, 
NMC-A and IMI), genes encoding metallo-β-lactamases 
(NDM-1, IMP, VIM, SPMand GIM), and genes encod-
ing the OXA-type carbapenemase (OXA-48). The prim-
ers used in PCR were previously described [5]. All of the 
positive PCR products were sequenced and compared 
with the reported sequences in GenBank (http://www.
ncbi.nlm.nih.gov/blast/).
Results
The results of PCR and sequencing found that 48 of the 
81 clinical CRE harbored carbapenemase genes, includ-
ing IMP-4 (n  =  23), IMP-8 (n  =  14), NDM-1 (n  =  5) 
and KPC-2 (n =  8). One K. pneumoniae isolate carries 
both IMP-4 and NDM-1 and one K. oxytoca isolate car-
ries both KPC-2 and IMP-8. No carbapenemase genes of 
VIM-, NMC-, GIM-, SPM-, SME-, GES-, IMI- and OXA-
48 were found in this study (Table  1). These genotypes 
were carried by different bacterial isolates, represented 
by 7 E. coli (38.9  %, 7/18), 26 K. pneumoniae (72.2  %, 
26/36), 14 E. cloacae (66.7 %, 14/21), 3 K. oxytoca (75.0 %, 
3/4) isolates. In addition, 1 E. areogenes isolate and 1 S. 
marcescens isolate has detected none carbapenemase 
genes (Table 1).
The three automated systems showed different ability of 
detecting/identifying CRE isolates in the study (Table 2). 
With AES, the MicroScan WalkAway and Vitek-2 showed 
a better sensitivity for the detection of CPE than the 
Phoenix 100. However, the Phoenix 100 AES had the best 
specificity for the detection of CPE (Table 3).
Further, the three automated systems differed signifi-
cantly in identification of the carbapenemase genotypes. 
The three automated systems showed high sensitivity in 
detection of NDM-1. All the isolates carrying NDM-1 
were accurately identified. While the isolates with KPC-2 
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were all detected by the MicroScan WalkAway system, 
Two isolates were missed by the Vitek-2 and Phoenix sys-
tems, respectively. The (Table 3) one missed by Phoenix 
was susceptible to imipenem (MIC, ≤1 μg/ml) and mero-
penem (MIC, ≤1 μg/ml), while the other one missed by 
Vitek-2 was resistant to ertapenem (MIC, ≥8 μg/ml) and 
imipenem (MIC, 8 μg/ml). The three automated systems 
showed a relative low rate of identification for IMP. Out 
of the 37 IMP positive isolates, 21 were missed by the 
Phoenix, 11 were missed by the Vitek-2 Compact, and 
only three were missed in the MicroScan WalkAway sys-
tem (Table 4). 
Discussion
CRE has been increasingly prevalent in China, and it is in 
critical need of rapid and accurate detection of CRE [18–
20]. Automated identification systems have been demon-
strated to have the ability to meet this requirement, but 
each system may perform differently, especially on iden-
tifying different genotypes of CRE [21–23].
In this study, we evaluated and compared the perfor-
mance of three automated identification systems, Micro-
Scan WalkAway, Phoenix 100 and Vitek-2, which are 
commonly used in China. The Vitek-2 system showed 
a higher identification rate than the MicroScan and 
the Phoenix on the identification of CRE. However, the 
MicroScan WalkAway’s AES showed a better sensitiv-
ity and specificity than the Vitek-2′s on the detection of 
CPE. Compared to the Vitek-2 and MicroScan WalkAway 
systems, the sensitivity of Phoenix 100 for the prediction 
of CRE and CPE needs to be improved.
The difference of accuracy in CRE detection among the 
three automated systems might be due to the number 
and type of carbapenems designed on the identification 
cards. The NC50 card of MicroScan WalkAway system 
has three carbapenems (imipenem, meropenem and 
ertapenem), the AST-GN card of Vitek-2 has two carbap-
enems (imipenem and ertapenem), and the NMIC/ID-4 
card of Phoenix 100 also has two carbapenems (imipe-
nem and meropenem). It was worth noting that Phoenix 
100 incorporated with imipenem and meropenem had 
a higher specificity but a lower sensitivity compared to 
the other two systems. In a previous study, Woodford 
reported that the sensitivity/specificity of Vitek-2 N054 
(containing ertapenem and meropenem) was 74/38  % 
[24], which is similar to the results in our study. We spec-
ulate that the combination of ertapenem with merope-
nem or imipenem has similar efficacy in the detection of 
Table 1 Composition of the carbapenemase genotypes in the CRE isolates of this study
a There was one K. pneumoniae isolate carrying both IMP-4 and NDM-1 enzymes
b There was one K. oxytoca carrying both KPC-2 and IMP-8 simultaneously
Species IMP-4 IMP-8 NDM-1 KPC-2
Number Percentage (%) Number Percentage (%) Number Percentage (%) Number Percentage (%)
E. coli 1 4.4 3 21.4 3 60.0 0 0.0
K. pneumoniaea 13 56.5 5 35.7 2 40.0 6 75.0
E. cloacae 8 34.8 5 35.7 0 0.0 1 12.5
E. areogenes 0 0.0 0 0.0 0 0.0 0 0.0
K. oxytocab 1 4.4 1 7.1 0 0.0 1 12.5
S. marcescens 0 0.0 0 0.0 0 0.0 0 0.0
Total 23 100.0 14 100.0 5 100.0 8 100.0
Table 2 Number of CRE isolates detected by each of the three automated identification systems in this study
Species Number Phoenix 100 Vitek-2 compact WalkAway 96 plus
ID CRE AES positive ID CRE AES positive ID CRE AES positive
E. coli 18 5 6 15 13 7 8
K. pneumoniae 36 16 19 36 34 31 33
E. cloacae 21 9 9 21 4 15 18
E. areogenes 1 0 0 1 1 0 1
K. oxytoca 4 3 3 4 4 3 4
S. marcescens 1 0 0 0 1 0 0
Total 81 33 37 77 57 56 64
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CRE, but the absence of ertapenem has a decreased sen-
sitivity. Also, different type of cards may carry different 
ability in CRE detection. Several studies have evalutated 
the different Vitek cards for detection of CRE, and found 
that there were different performance among those cards 
[25, 26].
In this study, four different carbapanemase genes (IMP-
4, IMP-8, KPC-2 and NDM-1) had been detected. All of 
the three automated systems showed a high sensitivity in 
detecting KPC-2 and NDM-1, but low sensitivity to IMP, 
especially with the Phoenix 100 system. A previous study 
shows the Phoenix 100 system has a better performance 
in detecting IMP [24]. This difference may be due to the 
complex resistant phenotypes of isolates. In our study, 
the IMP producers missed by the Phoenix system were 
susceptible to imipenem and meropenem, and had lower 
MICs than those could be detected. Those IMP produc-
ers missed by Vitek-2 had higher MIC of ertapenem 
(≥8 μg/ml). Notably, there were 2 IMP producers missed 
by all of the three systems, and these isolates had lower 
MICs of imipenem, meropenem and ertapenem (≤1 μg/
ml). Therefore, other methods should be performed 
together to increase the identification ability of IMP pro-
ducers when these systems are using in clinical labs.
It should be noted that isolates determined as CRE by 
MicroScan WalkAway and Phoenix systems were less 
than those promoted as carbapenemase positive by AES. 
This result may be due to the sensitivity of the systems, 
which cannot discriminate some isolates with the inter-
mediate of carbapanems. The shortcoming might be 
overcome via some complementary tests, such as addi-
tion of antimicrobial susceptibility discs and PCR.
Automated identification systems enable clinical 
microbiology laboratories to quickly and efficiently iden-
tify bacteria and characterize their drug susceptibilities. 
Automated identification systems should ideally achieve 
an accuracy rate of no less than 90  % in comparison to 
reference methods [27]. Our results suggest that the 
Vitek-2 and MicroScan WalkAway systems have better 
performance than the Pheonix 100 system on the iden-
tification of CRE, and the MicroScan WalkAway has the 
best sensitivity on the prediction of CPE. However, addi-
tional tests are required for the Pheonix 100 system.
In addition, our results indicate that the three systems 
carry different reliabilities depending upon the variety 
of the bacterial species. Previous studies suggest that 
both the Phoenix and the MicroScan WalkAway-96 sys-
tems are capable of providing accurate susceptibility test 
results for gram-negative bacilli with a wide array of anti-
microbial agents [28]. However, our study showed that 
the Phoenix system was lower sensitivity in the identifi-
cation of CRE than the others. Nonetheless, our findings 
Table 3 Performance of  the three automated identification systems in  detection of  carbapenemase production in  the 
CRE isolates of this study
Automated systems AES positive/negative No. of isolates with carbapenem resistance 
mechanism





Phoenix100 Positive 26 11 54.2 66.7
Negative 22 22
Vitek-2 compact Positive 36 21 75.0 36.4
Negative 12 12
WalkAway 96 plus Positive 45 19 93.8 42.4
Negative 3 14
Table 4 Ability of the three automated systems in detection of the carbapenemase genotypes in the CRE isolates of this 
study
Carbapenemase genotypes Number of isolates
Vitek-2 compact MicroScan walkaway Phoenix 100
Positive Negative Positive Negative Positive Negative
IMP-4 (n = 23) 14 9 21 2 9 14
IMP-8 (n = 14) 12 2 13 1 7 7
KPC-2 (n = 8) 7 1 8 0 7 1
NDM-1 (n = 5) 5 0 5 0 5 0
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suggest that while automated systems can provide rapid 
results for improved patient care, comparative studies 
should be conducted to evaluate the preference and relia-
bility of the instruments for further improvement in their 
performance. Meanwhile, the results of our PCR screen-
ing showed limited diversity in the carbapenemase genes. 
However, they could covered the diversity of the kinds of 
resistance genes found in China [29, 30]. Therefore, our 
results will be of valuable reference in China.
Conclusions
In conclusion, this is the first report that evaluates the 
performance of three automated identification systems 
commonly used in China. Our study will benefit clinical 
laboratories with the detection of CRE. And other tests 
should be combined to increase the accuracy when the 
three systems are used.
Abbreviations
PCR: polymerase chain reaction; CRE: carbapenem-resistant Enterobacte-
riaceae; CPE: carbapenemase-producing Enterobacteriaceae; KPC: Klebsiella 
pneumoniae carbapenemase; NDM-1: New Delhi metallo-beta-lactamase-1; 
VIM: verona integron–encoded metallo-β-lactamase; IMP: active on imipe-
nem; SPM: Sao Paulo metallo-β-lactamase; GIM: German imipenemase; GES: 
Guiana extended spectrum; SME: Serratia marcescens enzyme; NMC-A: not 
metalloenzyme carbapenemase; IMI: imipenem-hydrolyzingβ-lactamase; 
OXA-48: oxacillinase-48; MDR: multi-drug resistant; XDR: extensively drug-
resistant; AST: antimicrobial susceptibility testing; CLSI: Clinical and Laboratory 
Standards Institute; AES: advanced expert system; MIC: minimum inhibitory 
concentration.
Authors’ contributions
All authors contributed to this work. All authors read and approved the final 
manuscript.
Author details
1 Department of Clinical Laboratory, Fujian Medical University Union 
Hospital, 29 Xinquan Rd., Fuzhou 350001, Fujian, People’s Republic of China. 
2 Medical Technology and Engineering College, Fujian Medical University, 
Fuzhou 350004, Fujian, People’s Republic of China. 
Acknowledgements
We thank the dedicated staff members at Clinical Microbiology, Fujian Medical 
University Union Hospital for their technical support.
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
There is no additional data and materials, except those in the sections of 
“Methods” and “Results”.
Funding
This study was supported by the National Natural Science Foundation of 
China (Grant No. 81201328), the Fujian Provincial Funds for Distinguished 
Young Scientists in Colleges and Universities, China (Grant No. JA13134), 
and the Medical Elite Cultivation Program of Fujian, China (Grant No. 
2015-ZQN-ZD-15).
Received: 21 March 2016   Accepted: 8 June 2016
References
 1. Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican 
M, Cornaglia G, Garau J, Gniadkowski M, Hayden MK, et al. Clinical epi-
demiology of the global expansion of Klebsiella pneumoniae carbapen-
emases. Lancet Infect Dis. 2013;13(9):785–96.
 2. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae 
carbapenemase-producing bacteria. Lancet Infect Dis. 2009;9(4):228–36.
 3. Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos 
GL. Carbapenemases in Klebsiella pneumoniae and other Enterobac-
teriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev. 
2012;25(4):682–707.
 4. Goel N, Wattal C, Oberoi JK, Raveendran R, Datta S, Prasad KJ. Trend 
analysis of antimicrobial consumption and development of resistance 
in non-fermenters in a tertiary care hospital in Delhi, India. J Antimicrob 
Chemother. 2011;66(7):1625–30.
 5. Zhao ZC, Xu XH, Liu MB, Wu J, Lin J, Li B. Fecal carriage of carbapenem-
resistant Enterobacteriaceae in a Chinese university hospital. Am J Infect 
Control. 2014;42(5):e61–4.
 6. Nordmann P, Poirel L. Emerging carbapenemases in Gram-negative 
aerobes. Clin Microbiol Infect. 2002;8(6):321–31.
 7. Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, 
Steward CD, Alberti S, Bush K, Tenover FC. Novel carbapenem-hydrolyz-
ing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Kleb-
siella pneumoniae. Antimicrob Agents Chemother. 2001;45(4):1151–61.
 8. Nordmann P, Naas T, Poirel L. Global spread of Carbapenemase-produc-
ing Enterobacteriaceae. Emerg Infect Dis. 2011;17(10):1791–8.
 9. Hu F, Chen S, Xu X, Guo Y, Liu Y, Zhu D, Zhang Y. Emergence of carbape-
nem-resistant clinical Enterobacteriaceae isolates from a teaching hospital 
in Shanghai, China. J Med Microbiol. 2012;61(Pt 1):132–6.
 10. Wang X, Chen G, Wu X, Wang L, Cai J, Chan EW, Chen S, Zhang R. 
Increased prevalence of carbapenem resistant Enterobacteriaceae in 
hospital setting due to cross-species transmission of the bla NDM-1 
element and clonal spread of progenitor resistant strains. Front Microbiol. 
2015;6:595.
 11. Jin WY, Jang SJ, Lee MJ, Park G, Kim MJ, Kook JK, Kim DM, Moon DS, 
Park YJ. Evaluation of VITEK 2, MicroScan, and Phoenix for identifica-
tion of clinical isolates and reference strains. Diagn Microbiol Infect Dis. 
2011;70(4):442–7.
 12. Chen S, Xia P, Feng W. J C: spread of carbapenemase-producing Entero-
bacteria in a Southwest Hospital in China. Ann Clin Microbiol Antimicrob. 
2014;12(13):42.
 13. Zong Z, Wang X, Deng Y, Zhou T. Misidentification of Burkholderia pseu-
domallei as Burkholderia cepacia by the VITEK 2 system. J Med Microbiol. 
2012;61(Pt 10):1483–4.
 14. Zong Z. Nosocomial peripancreatic infection associated with Shewanella 
xiamenensis. J Med Microbiol. 2011;60(9):1387–90.
 15. Li W, Wu H, Sun G. Increasing occurrence of antimicrobial resistant hyper-
virulent (hypermucoviscous) Klebsiella pneumoniae isolates in China. Clin 
Infect Dis. 2014;58(2):225–32.
 16. CLSI: Performance standards for antimicrobial susceptibility testing, 21th 
informational supplement (M100-S22). 2012, Wayne, PA: CLSI.
 17. Li B, Sun JY, Liu QZ, Han LZ, Huang XH, Ni YX. High prevalence of CTX-M 
beta-lactamases in faecal Escherichia coli strains from healthy humans in 
Fuzhou, China. Scand J Infect Dis. 2011;43(3):170–4.
 18. Sun Y, Li M, Chen L, Chen H, Yu X, Ye J, Zhang Y, Ma C, Zhou T. Preva-
lence and molecular characterization of carbapenemase-producing 
gram-negative bacteria from a university hospital in China. Infect Dis. 
2016;48(2):138–46.
 19. Li B, Xu XH, Zhao ZC, Wang MH, Cao YP. High prevalence of metallo-
β-lactamase among carbapenem-resistant Klebsiella pneumoniae in a 
teaching hospital in China. Can J Microbiol. 2014;60(10):691–5.
 20. Cai JC, Zhang R, Hu YY, Zhou HW, Chen GX. Emergence of Escherichia coli 
sequence type 131 isolates producing KPC-2 carbapenemase in China. 
Antimicrob Agents Chemother. 2014;58(2):1146–52.
 21. Bulik CC, Fauntleroy KA, Jenkins SG, Abuali M, LaBombardi VJ, Nicolau 
DP, Kuti JL. Comparison of meropenem MICs and susceptibilities for 
carbapenemase-producing Klebsiella pneumoniae isolates by various test-
ing methods. J Clin Microbiol. 2010;48(7):2402–6.
Page 6 of 6He et al. Ann Clin Microbiol Antimicrob  (2016) 15:40 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 22. Doern CD, Dunne WM, Burnham CAD. Detection of Klebsiella pneumo-
niae Carbapenemase (KPC) production in Non-Klebsiella pneumoniae 
Enterobacteriaceae isolates by use of the phoenix, vitek 2, and disk diffu-
sion methods. J Clin Microbiol. 2011;49(3):1143–7.
 23. Woodford N, Eastaway AT, Ford M, Leanord A, Keane C, Quayle RM, Steer 
JA, Zhang J, Livermore DM. Comparison of BD Phoenix, vitek 2, and 
microscan automated systems for detection and inference of mecha-
nisms responsible for carbapenem resistance in Enterobacteriaceae. J 
Clin Microbiol. 2010;48(8):2999–3002.
 24. Heritier C, Poirel L, Fournier PE, Claverie JM, Raoult D, Nordmann P. 
Characterization of the naturally occurring oxacillinase of Acinetobacter 
baumannii. Antimicrob Agents Chemother. 2005;49(10):4174–9.
 25. Koizumi A, Kasahara K, Komatsu Y, et al. Evaluation of the vitek 2 
AST-N269 card for detection of meropenem resistance in imipenem-
susceptible meropenem-resistant Enterobacteriaceae. J Clin Microbiol. 
2013;51(11):3908.
 26. Harino T, Kayama S, Kuwahara R, et al. Meropenem resistance in 
imipenem-susceptible meropenem-resistant Klebsiella pneumoniae iso-
lates not detected by rapid automated testing systems. J Clin Microbiol. 
2013;51:2735–8.
 27. Carroll KC, Weinstein MP. Manual and automated systems for detec-
tion and identification of microoganisms. Manual Clin Microbiol. 
2007;1:192–217.
 28. Meyer III WA, Lockwood D, Brasso W, Reuben J. Abstr 100th General meet-
ing of the American Society for Microbiology [abstract]. Microbiol. 2000: 
C-309.
 29. Li H, Zhang J, Liu Y, Zheng R, Chen H, Wang X, Wang Z, Cao B, Wang H. 
Molecular characteristics of carbapenemase-producing Enterobacte-
riaceae in China from 2008 to 2011: predominance of KPC-2 enzyme. 
Diagn Microbiol Infect Dis. 2014;78(1):63–5.
 30. Hu L, Zhong Q, Shang Y, Wang H, Ning C, Li Y, Hang Y, Xiong J, Wang X, 
Xu Y, Qin Z, Parsons C, Wang L, Yu F. The prevalence of carbapenemase 
genes and plasmid-mediated quinolone resistance determinants in 
carbapenem-resistant Enterobacteriaceae from five teaching hospitals in 
central China. Epidemiol Infect. 2014;142(9):1972–7.
